Drug intelligence / Profile preview

pollen allergoid

Development stage
Unknown
Lead developer
Medical University of Bialystok
Modality
Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Subcutaneous
01

Overview

Pollen allergoids are chemically modified allergen extracts used in subcutaneous allergen immunotherapy (SCIT) for the treatment of seasonal allergic rhinitis. They are typically produced by polymerizing native pollen allergens (such as grass or tree pollen) using agents like glutaraldehyde or formaldehyde. This chemical modification significantly reduces the extract's IgE-binding capacity (allergenicity), thereby minimizing the risk of systemic allergic reactions during administration. Crucially, the modification preserves the T-cell epitopes (immunogenicity), allowing the drug to effectively modulate the immune system by inducing regulatory T-cells and shifting the cytokine profile from a Th2-driven response toward immune tolerance. These products are often adsorbed onto aluminum hydroxide adjuvants to enhance their immunomodulatory effects and are administered in either pre-seasonal or year-round maintenance regimens.

Brand names
AllergovitPurethalDepigoid
Other names
Allergen allergoidModified allergen extractPolymerized allergen extract
02

Targets

BCR (Immunoglobulin G B Cell Receptor)CLR (C-type lectin receptors)Timothy grass-specific IgE (Timothy grass-specific immunoglobulin E)IgE (Immunoglobulin E)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on pollen allergoid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pollen allergoid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call